base editing
-
Base-Editing Biotech Beam Restructures, Narrowing Pipeline & Cutting 20% of Staff
Sickle cell disease is among the Beam Therapeutics programs spared, and here the company needs to show differentiation from genetic medicines under FDA review from Vertex Pharmaceuticals and Bluebird Bio. Meanwhile, Beam aims to find partners for its research in allogeneic cancer cell therapies and hepatitis B.
-
Pfizer, Bayer each strike up deals to add in-vivo gene editing to pipeline mix
As the annual J.P. Morgan HealthCare Conference kicked off Monday, two pharma giants unveiled deals that give them access to in-vivo gene editing technologies. Pfizer is teaming up with Beam Therapeutics to develop new base-editing therapies while Bayer hopes to develop new medicines with the in-vivo CRISPR editing tools of Mammoth Biosciences.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Magenta, Beam partner to explore use of antibody-based conditioning drug for gene therapies
The companies will explore the use of MGTA-117, which is currently in preclinical IND-enabling studies as a conditioning regimen for patients receiving gene therapy designed to be less toxic than the current standard of chemotherapy or radiation.
-
Beam Therapeutics raises $180M in IPO
The company was founded to develop base editing, a form of gene editing that alters genes at the single-letter level rather than using the “cutting” technique typical of CRISPR/Cas9. Beam had filed to go public in September, aiming at raising $100 million.